◎ Sugi Atlas

Atlas / Drug / Alemtuzumab

Alemtuzumab

drug
On this page

Also known as Alemtuzumab (genetical recombination)Allo 647Campath mabcampathCAMPATH-1HlemtradaGZ-402673GZ402673LDP-03Mabcampath

Summary

Alemtuzumab (CHEMBL1201587) is an approved antibody (ATC L04AG06) targeting CD52; indicated across 67 conditions including b-cell chronic lymphocytic leukemia and multiple sclerosis; with CIViC clinical evidence for 1 variant-indication association (e.g. TP53 Mutation in chronic lymphocytic leukemia).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Antibody
  • ATC class: L04AG06
  • Targets: 1 (CD52)
  • Indications: 67 conditions
  • Clinical trials: 247
  • Precision-oncology evidence (CIViC): 1 variant–indication association

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201587
NameAlemtuzumab
TypeAntibody
Max phase4
ATCL04AG06

Also known as: Alemtuzumab, Alemtuzumab (genetical recombination), Allo 647, Campath mabcampath, CAMPATH-1H, lemtrada, GZ-402673, GZ402673, LDP-03, Lemtrada, Mabcampath, ALEMTUZUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
CD52CD52Binding0.1%P31358

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): CD52.

Top Reactome pathways

3 total, by targets touching each:

PathwayTargetsGenes
Post-translational modification: synthesis of GPI-anchored proteins1CD52
Metabolism of proteins1CD52
Post-translational protein modification1CD52

Dominant GO biological processes

GO termTargets
positive regulation of cytosolic calcium ion concentration1
respiratory burst1

Indications & clinical

Indications

67 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
B-cell chronic lymphocytic leukemia4MONDO:0004948EFO:0000095
multiple sclerosis4MONDO:0005301MONDO:0005301
peripheral T-cell lymphoma, not otherwise specified3MONDO:0004964EFO:0000211
leukemia3MONDO:0005059EFO:0000565
lymphoma3MONDO:0005062EFO:0000574
relapsing-remitting multiple sclerosis3MONDO:0005314EFO:0003929
myelodysplastic syndrome3MONDO:0018881EFO:0000198
acute myeloid leukemia3MONDO:0018874EFO:0000222
angioimmunoblastic T-cell lymphoma3MONDO:0004977EFO:0000255
nasal cavity and paranasal sinus lethal midline granuloma3MONDO:0006828MONDO:0019472
sickle cell disease3MONDO:0011382MONDO:0011382
graft versus host disease2MONDO:0013730EFO:0004599
acute lymphoblastic leukemia2MONDO:0004967EFO:0000220
immune system disorder2MONDO:0005046EFO:0000540
Hodgkins lymphoma2MONDO:0004952EFO:0000183
T-cell acute lymphoblastic leukemia2MONDO:0004963EFO:0000209
aplastic anemia2MONDO:0015909HP:0001915
Crohn disease2MONDO:0005011EFO:0000384
diffuse large B-cell lymphoma2MONDO:0018905EFO:0000403
neoplasm2MONDO:0005070EFO:0000616
liver disorder2MONDO:0005154EFO:0001421
lymphoid neoplasm2MONDO:0005157EFO:0001642
lymphoid leukemia2MONDO:0005402EFO:0004289
inclusion body myositis2MONDO:0007827EFO:0007323
Sezary syndrome2MONDO:0017844EFO:1000785
mycosis fungoides2MONDO:0009691EFO:1001051
acute erythroid leukemia2MONDO:0017858EFO:1001257
thalassemia2MONDO:0000984EFO:1001996
histiocytosis2MONDO:0002637HP:0100727
beta thalassemia2MONDO:0019402Orphanet:848
Waldenstrom macroglobulinemia2MONDO:0100280EFO:0009441
myeloproliferative neoplasm2MONDO:0020076EFO:0002428
autoimmune thrombocytopenic purpura2MONDO:0008558EFO:0007160
autoimmune hemolytic anemia2MONDO:0020108EFO:1001264
prolymphocytic leukemia2MONDO:0001023MONDO:0001023
kidney cancer2MONDO:0002367MONDO:0002367
hematopoietic and lymphoid system neoplasm2MONDO:0002334MONDO:0044881
B-cell acute lymphoblastic leukemia2MONDO:0004947EFO:0000094
type 1 diabetes mellitus2MONDO:0005147MONDO:0005147
severe combined immunodeficiency2MONDO:0015974MONDO:0015974
osteopetrosis2MONDO:0017198MONDO:0017198
chronic granulomatous disease2MONDO:0018305MONDO:0018305
inherited hemoglobinopathy2MONDO:0019050MONDO:0044348
chronic kidney disease2MONDO:0005300MONDO:0024327
neuroblastoma1MONDO:0005072EFO:0000621
plasma cell myeloma1MONDO:0009693EFO:0001378
kidney disorder1MONDO:0005240EFO:0003086
anemia1MONDO:0002280EFO:0004272
non-Hodgkin lymphoma1MONDO:0018908EFO:0005952
rheumatoid arthritis1MONDO:0008383EFO:0000685
vasculitis1MONDO:0018882EFO:0006803
T-cell prolymphocytic leukemia1MONDO:0019468EFO:1000560
kidney failure1MONDO:0001106EFO:1002048
peritoneal neoplasm1MONDO:0006901MONDO:0002087
fallopian tube neoplasm1MONDO:0021092MONDO:0002158
ovarian cancer1MONDO:0008170MONDO:0008170
Fanconi anemia1MONDO:0019391MONDO:0019391
neoplasm of mature B-cells1MONDO:0004949EFO:0000096
neuroepithelial neoplasm0MONDO:0021193MONDO:0021193
epidermolysis bullosa0MONDO:0006541EFO:1000690

7 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 247.

Phase distribution

PhaseTrials
PHASE2121
PHASE1/PHASE240
Not specified26
PHASE123
PHASE416
PHASE312
PHASE2/PHASE35
EARLY_PHASE14

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00113269PHASE4COMPLETEDSafety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients
NCT00166712PHASE4TERMINATEDA Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression
NCT00177138PHASE4TERMINATEDUse of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation
NCT00331162PHASE4COMPLETEDStudy of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
NCT00681343PHASE4COMPLETEDThymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation
NCT00685061PHASE4COMPLETEDThymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation
NCT01172418PHASE4COMPLETEDRandomized Trial of 2 Antibody Induction Steroid Avoidance Protocols
NCT01213329PHASE4TERMINATEDImmunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab
NCT01395316PHASE4COMPLETEDAlemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
NCT01405807PHASE4UNKNOWNAlemtuzumab for ANCA Associated Refractory Vasculitis
NCT01729494PHASE4COMPLETEDBelatacept Early Steroid Withdrawal Trial
NCT01757574PHASE4WITHDRAWNAlemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)
NCT02205489PHASE4COMPLETEDManagement Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA
NCT02255656PHASE4COMPLETEDPhase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
NCT02419378PHASE4COMPLETEDAlemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
NCT03135249PHASE4COMPLETEDSequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis
NCT03477500PHASE3ACTIVE_NOT_RECRUITINGRandomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)
NCT00046683PHASE3COMPLETEDEfficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
NCT00147381PHASE3COMPLETEDEffectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection
NCT00226512PHASE3WITHDRAWNTo Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning
NCT00316810PHASE3COMPLETEDSimultaneous Pancreas-kidney Transplantation With Campath Protocol
NCT00454480PHASE2/PHASE3COMPLETEDCombination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
NCT00530348PHASE3COMPLETEDComparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
NCT00548405PHASE3COMPLETEDComparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
NCT00725231PHASE3UNKNOWNImmunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
NCT00749112PHASE2/PHASE3COMPLETEDAlemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias
NCT00775931PHASE2/PHASE3COMPLETEDAllogeneic Transplantation For Severe Osteopetrosis
NCT00930553PHASE3COMPLETEDAn Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
NCT01019876PHASE2/PHASE3COMPLETEDRisk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
NCT01120028PHASE2/PHASE3COMPLETEDCampath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy
NCT01333358PHASE3UNKNOWNEvaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients
NCT01877837PHASE3COMPLETEDStem Cell Transplantation for Sickle Cell Anemia
NCT03368664PHASE3TERMINATEDA Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
NCT00408447PHASE2ACTIVE_NOT_RECRUITINGStem Cell Transplant in Sickle Cell Disease and Thalassemia
NCT00692939PHASE1/PHASE2RECRUITINGAutologous Stem Cell Transplantation for Crohn’s Disease
NCT00977691PHASE1/PHASE2ACTIVE_NOT_RECRUITINGHaploidentical PBMC Transplant for Severe Congenital Anemias
NCT01361711PHASE2ACTIVE_NOT_RECRUITINGAlemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
NCT01499888PHASE1/PHASE2ACTIVE_NOT_RECRUITINGPh I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)
NCT01659606PHASE2ACTIVE_NOT_RECRUITINGRadiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
NCT01962415PHASE2RECRUITINGReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Clinical evidence (CIViC)

Variant × indication × effect (1 predictive associations from 1 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
TP53 MutationChronic Lymphocytic LeukemiaSensitivity/ResponseAlemtuzumabCIViC BEID1481

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot